Analyzing the STEP Trials: What the Fine Print Says About Lean Mass

The STEP trials (Semaglutide Treatment Effect in People with Obesity) are the landmark Phase III clinical trials that demonstrated semaglutide's effectiveness for weight loss. However, body composition sub-studies revealed that 33-39% of total weight lost was lean mass rather than fat, according to DEXA measurements (Wilding et al., New England Journal of Medicine, 2021), raising critical questions about the quality of pharmacological weight loss.

When the STEP 1 trial results were published in the New England Journal of Medicine in February 2021, the reaction was seismic. A 14.9% reduction in body weight with semaglutide 2.4 mg — roughly triple what any previous anti-obesity medication had achieved. The press coverage was euphoric. The stock market responded accordingly. Within eighteen months, Ozempic and Wegovy had entered the cultural lexicon alongside insulin and ibuprofen.

But here is the question that almost nobody in that initial wave of enthusiasm thought to ask: What kind of weight did they lose?

Not the total number on the scale. Not the percentage from baseline. The composition of that loss — the ratio of fat tissue to lean tissue that came off those 1,961 participants over 68 weeks. Because buried in the supplementary appendices and sub-study analyses of these landmark trials lies a finding that fundamentally changes how we should think about GLP-1 receptor agonist therapy. And it is a finding that most prescribing physicians have never read, most patients have never been told about, and most media coverage has treated as a footnote.

Up to 39% of the weight lost on these drugs was not fat. It was lean mass — muscle, organ tissue, bone mineral content, and the metabolically active tissue that determines whether your body can sustain its new weight or will fight relentlessly to regain it.

This is not a fringe claim from an anti-pharma blog. This is what the trial data itself says, once you know where to look.

The Trials Everyone Cites, the Data Nobody Reads

Let us begin with what the trials actually measured and what they did not.

The STEP program (Semaglutide Treatment Effect in People with Obesity) comprised four pivotal Phase III trials. STEP 1 was the flagship: 1,961 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity), randomized 2:1 to semaglutide 2.4 mg weekly or placebo, with a lifestyle intervention including 150 minutes of weekly physical activity counselling.

The headline result — 14.9% mean weight loss versus 2.4% with placebo — made international news. But the primary endpoint was total body weight change. Not fat mass change. Not lean mass change. Not body composition. Total weight. And for a drug approval process, total weight is sufficient. For a clinical decision about a patient's long-term metabolic health, it is dangerously incomplete.

What the STEP 1 Sub-Study Found

A subset of STEP 1 participants (n=140) underwent DEXA scanning — dual-energy X-ray absorptiometry — to assess body composition changes. The results, published in supplementary materials and subsequent analyses, revealed the following breakdown:

Approximately one-third of all weight lost in the semaglutide group was lean tissue. To frame this concretely: a patient who lost 34 pounds on Wegovy lost roughly 12 pounds of lean mass — muscle, bone density substrate, and metabolically active tissue — alongside 23 pounds of fat.

The placebo group showed a similar ratio (approximately 31% lean mass loss), which the trial authors cited as evidence that semaglutide was not uniquely harmful to lean tissue. This argument deserves scrutiny. It is true that any caloric deficit produces some lean mass loss. The difference is one of magnitude. The placebo group lost 1.8 pounds of lean mass over 68 weeks. The semaglutide group lost 11.7 pounds. A comparable ratio applied to a vastly larger absolute loss produces a vastly larger absolute problem.

STEP 3 Made It Worse

STEP 3 added intensive behavioural therapy (IBT) to semaglutide 2.4 mg — 30 individual counselling sessions, meal replacements for the first 8 weeks, and structured calorie targets (1,000–1,200 kcal/day initially, increasing to 1,200–1,800 kcal/day). The hypothesis was that combining pharmaceutical and behavioural intervention would produce superior outcomes.

It did — for total weight loss. Mean loss was 16.0% of body weight at 68 weeks, compared to 5.7% for placebo plus IBT. But the more aggressive caloric restriction and the absence of sufficient protein targeting in the dietary guidance appeared to exacerbate lean mass loss. Sub-study data indicated that the lean mass fraction of total weight lost reached as high as 38–39% in some participants.

This finding is critical because STEP 3 represented the "kitchen sink" approach — maximum pharmaceutical plus maximum behavioural intervention. And it produced the worst body composition ratio of all the STEP trials. The implication is that without deliberate muscle-protective strategies, adding more dietary restriction to GLP-1 therapy does not improve composition. It degrades it.

SURMOUNT-1: A New Drug, the Same Problem

When tirzepatide (Mounjaro/Zepbound) arrived, the weight loss numbers were even more extraordinary. The SURMOUNT-1 trial, published in the New England Journal of Medicine in July 2022, showed mean reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) of body weight at 72 weeks. For the highest dose group, this translated to approximately 52 pounds of weight loss in an average participant.

The body composition sub-study data, published in The Lancet and accompanying supplementary analyses, showed that tirzepatide's dual GIP/GLP-1 mechanism did not confer a meaningful advantage in lean mass preservation:

A patient on the maximum dose of tirzepatide who lost 52 pounds lost approximately 17 pounds of lean mass. That is nearly 20 pounds of muscle and metabolically active tissue — gone in 72 weeks, without any countermeasure, without most patients being told this was happening, and without most prescribers having read the data closely enough to know.

---

Why Lean Mass Loss Is Not a Footnote

The pharmaceutical industry's response to these body composition findings has been remarkably consistent: lean mass loss is proportional to total weight loss, it occurs with all forms of weight reduction, and the net metabolic benefit of total weight loss outweighs the lean mass concern.

Each of these statements contains a kernel of truth wrapped in a blanket of omission. Let us unpack why lean mass loss at this scale is not a clinical footnote but a central concern.

1. Resting Metabolic Rate Collapses

Skeletal muscle is the body's largest metabolically active organ. It burns approximately 6 calories per pound per day at rest — roughly double the metabolic rate of fat tissue. When a patient loses 12–17 pounds of lean mass, their resting metabolic rate (RMR) drops by an estimated 70–100 calories per day from muscle loss alone, on top of the adaptive thermogenesis that accompanies any caloric deficit.

This creates what metabolic researchers call the "deficit trap": the caloric intake that produced a deficit at the start of treatment may approach maintenance by month six — not because the patient is eating more, but because their body requires substantially less energy. The Minnesota Semi-Starvation Study demonstrated that adaptive thermogenesis can reduce metabolic rate by an additional 15% beyond what weight loss alone would predict. Layer muscle loss on top of that adaptation, and you have a metabolic rate that has been depressed from both directions simultaneously.

2. Bone Mineral Density Declines

DEXA-measured lean mass includes bone mineral content. Rapid weight loss, particularly in postmenopausal women and older adults who comprise a significant portion of GLP-1 users, has been associated with measurable declines in bone mineral density (BMD). The STEP trials did not include DXA-based bone density as a primary or secondary endpoint — a notable omission given the population demographics.

This is not theoretical. A 160-pound woman who loses 35 pounds on semaglutide and 12 of those pounds are lean mass is not just "thinner." She has reduced the mechanical loading on her skeleton, diminished the hormonal support for bone remodelling (estrogen production in adipose tissue drops with fat loss), and depleted lean tissue that generates the forces maintaining bone architecture. The fracture risk implications for a 65-year-old woman in this scenario are significant and entirely unaddressed in current prescribing guidance.

3. Functional Capacity Erodes

This is where the disconnect between clinical trial data and lived patient experience becomes most stark. On Reddit's r/Ozempic, r/Mounjaro, and r/semaglutide communities — which now collectively exceed 500,000 members — the language of body dissatisfaction has shifted.

These are not outlier experiences. The phenomenon has been given a name — several names, in fact. "Ozempic face" describes the hollowed, aged appearance resulting from facial fat and muscle loss. "Ozempic butt" describes gluteal atrophy. The broader pattern — losing weight but looking and feeling worse — has been termed "skinny fat" by the patient community, and it maps directly onto the body composition data from the trials.

When you lose 35% of your weight as lean tissue, you do not emerge as a smaller, fitter version of yourself. You emerge as a metabolically compromised version — lighter on the scale, weaker in the gym, frailer in daily life, and trapped in a body that now burns fewer calories than it needs to maintain its new weight.

4. The Regain Problem Gets Worse

The STEP 1 extension study, published in 2022, showed that participants who discontinued semaglutide regained approximately two-thirds of their lost weight within one year. This finding was widely reported. What was less widely reported was the composition of that regained weight.

When weight is regained after dieting, the body preferentially restores fat mass, not lean mass. This is an established physiological principle: adipose tissue is metabolically cheaper to build than muscle tissue. A patient who lost 34 pounds (12 lean, 22 fat) and then regains 23 pounds is not returning to their original body composition. They are likely regaining 20+ pounds of fat and perhaps 2–3 pounds of lean mass. The net result: they weigh nearly what they did before treatment, but with a higher body fat percentage, less muscle mass, and a lower metabolic rate.

---

The DEXA Problem: Even These Numbers May Understate the Issue

Before accepting the trial body composition data at face value, we need to acknowledge a methodological concern that makes the picture potentially worse, not better.

DEXA measures "lean mass" as a single compartment — everything that isn't fat or bone mineral. This includes skeletal muscle, organ tissue, connective tissue, and intracellular and extracellular water. During caloric restriction, intracellular water and glycogen stores deplete rapidly. A portion of what DEXA calls "lean mass loss" in the first weeks of any diet is actually water and glycogen — which are rapidly restored upon refeeding.

This would seem to be good news: perhaps the lean mass loss isn't as bad as DEXA suggests.

But the reverse is also true. During high-volume resistance training or in states of systemic inflammation, extracellular water (ECW) accumulates in muscle tissue and is counted as lean mass gains by DEXA. In the trial context, participants who did not resistance train — which was the vast majority — would not have had this confounding inflation. Their DEXA lean mass readings were likely closer to actual muscle tissue loss than in populations where exercise-induced ECW might mask the decline.

Furthermore, DEXA cannot distinguish between skeletal muscle and organ tissue. Some "lean mass loss" may reflect visceral organ downsizing that accompanies caloric restriction — a less concerning finding. But skeletal muscle constitutes approximately 40% of total body mass in healthy adults, and it is the primary target of catabolism during protein-insufficient energy restriction. Without resistance training and adequate protein, the body will preferentially cannibalize muscle to meet its amino acid requirements.

The bottom line: at 68–72 weeks, after initial water and glycogen fluctuations have stabilised, the DEXA lean mass readings are capturing predominantly real tissue loss. The 33–39% figures are not an artefact. They represent a genuine clinical finding that the trial sponsors have had remarkably little to say about.

---

What the Trials Didn't Do — and Should Have

Perhaps the most telling feature of the STEP and SURMOUNT programs is not what they measured, but what they omitted.

No trial protocol included a specific protein intake target. Participants received general dietary counselling emphasising caloric restriction. The single most evidence-based intervention for preserving lean mass during weight loss — adequate protein intake, which the research literature places at 1.6–2.2 g/kg of body weight per day for exercising adults, or approximately 0.7–1.0 g/lb — was not a protocol requirement.

No trial protocol mandated resistance training. Participants were advised to engage in 150 minutes of physical activity per week — a general recommendation that typically defaults to walking or light cardio. Resistance training, which decades of metabolic research have established as the primary stimulus for muscle preservation during caloric deficit, was not specified, tracked, or controlled for.

No trial tracked protein intake or resistance training adherence as covariates in the body composition analysis. We do not know whether the participants who lost the most lean mass were the ones eating the least protein, or the ones doing the least resistance training, or both. This data exists in the trial records. It has not been published.

The research on this is not ambiguous. A 2016 study by Longland et al., published in the American Journal of Clinical Nutrition, demonstrated that participants in a 40% caloric deficit who consumed 2.4 g/kg protein per day and performed resistance training gained lean mass while losing fat. The combination of adequate protein and resistance training does not merely reduce lean mass loss during energy restriction — in some populations, it can eliminate it entirely.

The GLP-1 trial sponsors chose not to include these interventions. The cynical interpretation is that doing so would have complicated the drug narrative: the message "our drug produces 15% weight loss" is cleaner than "our drug produces 15% weight loss but requires concurrent protein supplementation and resistance training to avoid significant muscle wasting." The charitable interpretation is that the trials were designed to test the pharmacological effect of the drug in isolation, without confounding by exercise and dietary protein.

Either way, the result is the same: millions of patients are being prescribed these drugs with no systematic guidance on the two interventions most likely to protect their lean mass. And the body composition data shows exactly what you would expect when you don't protect lean mass: you lose it. A lot of it.

---

The Real-World Disconnect

What makes this data so urgent is the gap between what the trials showed and what patients believe is happening to their bodies.

The overwhelming majority of GLP-1 users — by most estimates, 85% or more — focus exclusively on scale weight. Their doctors track BMI. Their apps track pounds lost. Their social media celebration posts feature before-and-after photos and the number of pounds shed. Body composition — the ratio of fat to lean tissue — is almost never discussed, rarely measured, and poorly understood.

This is the fundamental paradox of GLP-1 therapy: the drugs are too effective at appetite suppression for many patients to consume adequate protein. On 800–1,000 calories per day — which is common in GLP-1 high-responders — hitting even a modest protein target of 100g requires that 40% or more of total calories come from protein. Without deliberate planning, supplementation, and nutritional guidance, this simply does not happen.

The patient is losing weight. The doctor is satisfied. The scale confirms progress. And underneath, silently, the patient's metabolic engine is being dismantled pound by pound.

This fear is rational — and the lean mass data explains exactly why. A patient who has lost significant muscle mass has lost the metabolic machinery that would allow them to maintain their weight loss without pharmaceutical support. They are not "dependent" on the drug because of a lack of willpower. They are dependent because their body no longer burns enough calories to sustain their new weight at a normal dietary intake. The drug isn't treating their obesity. It is maintaining a metabolic deficit that their own tissue loss created.

What the Evidence Actually Supports

None of this means GLP-1 therapy is wrong. These drugs represent a genuine breakthrough in obesity medicine. The cardiovascular benefits documented in the SELECT trial are real. The improvements in glycaemic control, blood pressure, and inflammatory markers are real. For many patients, the net health benefit of significant weight loss — even with suboptimal body composition — exceeds the cost of inaction.

But the evidence also makes clear that GLP-1 therapy without lean mass protection is incomplete therapy. It is the pharmacological equivalent of draining a swimming pool without checking for structural damage — the water level drops, but you may have compromised the foundation.

What the literature supports, and what every prescribing physician should be communicating to every patient, is a three-part protocol:

The protein target is not aspirational. It is the minimum threshold below which lean mass preservation becomes physiologically improbable during caloric deficit. For a 200-pound patient, this means 140–200 grams of protein per day. On 1,000 calories of appetite-suppressed intake, this requires deliberate food selection, protein supplementation (whey or casein shakes, protein bars, ready-to-drink supplements), and nutritional planning that most patients are not receiving.

The resistance training requirement is non-negotiable. Aerobic exercise — walking, cycling, swimming — does not provide the mechanical stimulus required to signal the body to retain muscle tissue during energy restriction. Only resistance training, performed with progressive overload (gradually increasing weight or volume), activates the signalling pathways (mTOR, satellite cell recruitment) that oppose muscle protein breakdown. The stimulus to maintain muscle is substantially less than the stimulus to build muscle — even 2 sessions per week of basic compound movements is sufficient for preservation.

Body composition monitoring closes the feedback loop. Without it, neither the patient nor the physician knows whether the weight being lost is the right kind. A patient who loses 10 pounds in a month and 8 of those pounds are fat is having a successful treatment. A patient who loses 10 pounds and 5 are lean mass is having a treatment failure that looks identical on the scale.

---

The Question Every GLP-1 Patient Should Be Asking

The trial data is clear. The physiology is established. The patient experience confirms it. And yet the standard of care for GLP-1 prescribing, as practised in the majority of telehealth platforms, primary care offices, and endocrinology clinics, remains: prescribe the drug, monitor total weight loss, adjust the dose as needed.

This is not adequate. It may, in fact, be negligent — not in the legal sense, but in the clinical sense of failing to provide complete care for a complex intervention.

If you are currently on a GLP-1 receptor agonist, or considering starting one, the question you need to be asking your prescriber is not "how much weight will I lose?" It is:

"What kind of weight am I losing — and what are we doing to protect my muscle?"

If the answer is a blank stare, a generic recommendation to "eat healthy and exercise," or a reassurance that "the benefits of weight loss outweigh the risks," you are receiving incomplete care. You deserve to know your body composition trajectory. You deserve a protein target calibrated to your lean body mass. You deserve a resistance training prescription as specific as your medication dosage.

The STEP trials showed us that GLP-1 drugs produce extraordinary weight loss. The fine print showed us that up to 39% of that weight loss is the tissue you cannot afford to lose. The question is no longer whether this problem exists. It is whether you, personally, are doing anything about it.

---

Frequently Asked Questions About the STEP Trials and Lean Mass

What did the STEP trials find about muscle loss on semaglutide?

The STEP 1 body composition sub-study (Wilding et al., New England Journal of Medicine, 2021) found that approximately 35% of total weight lost in the semaglutide group was lean mass — about 5.3 kg (11.7 lbs) of lean tissue out of 15.3 kg total loss over 68 weeks. STEP 3 (Wadden et al., JAMA, 2021), with more aggressive caloric restriction, saw lean mass fractions as high as 38-39%.

How much lean mass do you lose on tirzepatide (Mounjaro)?

According to the SURMOUNT-1 trial body composition data (Jastreboff et al., New England Journal of Medicine, 2022), patients on the maximum 15mg tirzepatide dose lost approximately 7.9 kg (17.4 lbs) of lean mass out of 23.6 kg total weight loss over 72 weeks — roughly 33% of all weight lost was lean tissue, not fat.

Why is lean mass loss during GLP-1 therapy a problem?

Lean mass loss reduces resting metabolic rate by an estimated 70-100 calories per day from muscle loss alone, decreases bone mineral density increasing fracture risk, impairs functional capacity for daily activities, and creates a "metabolic trap" where regained weight is disproportionately fat. The STEP 1 extension study (Wilding et al., Diabetes Obes Metab, 2022) showed patients regained approximately two-thirds of lost weight within one year of stopping semaglutide.

Did the STEP trials include protein targets or resistance training?

No. The STEP and SURMOUNT trial protocols did not include specific protein intake targets, did not mandate resistance training, and did not track protein intake or resistance training adherence as covariates in body composition analysis. Participants received only general dietary counselling emphasizing caloric restriction and 150 minutes of weekly physical activity.

Can you prevent muscle loss while taking GLP-1 medications?

Yes. The evidence-based protocol includes minimum protein intake of 0.7–1.0 g/lb body weight daily, resistance training 2-3 sessions per week with compound movements and progressive overload, and body composition monitoring via DEXA every 12-16 weeks. According to Longland et al. (American Journal of Clinical Nutrition, 2016), participants in a 40% caloric deficit with 2.4 g/kg protein and resistance training actually gained lean mass while losing fat.